Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer

Koyama,Yoshihisa; Okayama,Hirokazu; Kumamoto,Kensuke; Saito,Katsuharu; Nakamura,Izumi; Ohki,Shinji; Takenoshita,Seiichi

doi:10.3892/etm_00000098

Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer

Authors:
- Yoshihisa Koyama
- Hirokazu Okayama
- Kensuke Kumamoto
- Katsuharu Saito
- Izumi Nakamura
- Shinji Ohki
- Seiichi Takenoshita
View Affiliations

Affiliations: Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000098
Pages: 627-633

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to examine the expression of endoglin (CD105) in resected gastric cancer and to evaluate the relationship between microvessel density (MVD) and tumor recurrence after surgery. One hundred and thirty-two patients who had undergone curative surgery for primary gastric cancer were immunohistochemically stained for CD105, and MVD was assessed based on the number of CD105-positive vessels. MMP-7 expression was also investigated to determine the relationship with MVD. High MVD was significantly correlated with worse relapse-free survival in all cases and stage I-II cases by log-rank test (p=0.0005 and p=0.0154, respectively). Furthermore, in stage I-II cases, high MVD was the only independent predictor for relapse-free survival by multivariate analysis of the Cox proportional hazard model [p=0.028; hazard ratio (HR)=4.582; 95% confidence interval (CI) 1.184-17.737]. Regarding the specific patterns of recurrence, high MVD was independently related to locoregional recurrence [p=0.011; odds ratio (OR)=15.208; 95% CI 1.886-122.662] and hematogenous recurrence (p=0.002; OR=5.718; 95% CI 1.875-17.442) by multivariate logistic analysis. However, the expression of MMP-7 or CD105 combined with MVD was associated with relapse-free survival, although these prognostic impacts were not maintained in multivariate analysis. In conclusion, MVD recognized by CD105 may be useful as a predictor for the recurrence of resected gastric cancer and may have a specific association with the development of locoregional and hematogenous recurrence.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Moriguchi S, Maehara Y, Korenaga D, Sugimachi K and Nose Y: Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1:341–346. 1992. View Article : Google Scholar : PubMed/NCBI
3.	Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 14:1931–1937. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D and Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 17:197–203. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B and Tonini G: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 57:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG and Gorter A: Expression of endoglin (CD105) in cervical cancer. Br J Cancer. 100:1617–1626. 2009. View Article : Google Scholar : PubMed/NCBI
7.	El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R and Saad RS: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol. 127:572–579. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N and Kumar S: Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 89:122–126. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L and Kumar S: Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol. 37:861–866. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni Z, Karakitsos P, Lazaris AC, Papachristodoulou A, Klonaris C and Gazouli M: Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer. 10:12–17. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Roy R, Zhang B and Moses MA: Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 312:608–622. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Overall CM and Kleifeld O: Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 6:227–239. 2006.
13.	Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med. 231:20–27. 2006.PubMed/NCBI
14.	Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
15.	Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
16.	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991.
17.	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar
18.	Huo N, Ichikawa Y, Kamiyama M, Ishikawa T, Hamaguchi Y, Hasegawa S, Nagashima Y, Miyazaki K and Shimada H: MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 177:95–100. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Nishizuka I, Ichikawa Y, Ishikawa T, Kamiyama M, Hasegawa S, Momiyama N, Miyazaki K and Shimada H: Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo. Cancer Lett. 173:175–182. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Lee S, Jilani SM, Nikolova GV, Carpizo D and Iruela-Arispe ML: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 169:681–691. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Clasper S, Royston D, Baban D, Cao Y, Ewers S, Butz S, Vestweber D and Jackson DG: A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 68:7293–7303. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H and Miyazaki M: Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas. 37:275–281. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H and Seon BK: Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother. 55:140–150. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H and Seon BK: Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer. 122:2266–2273. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Fonsatti E, Nicolay HJ, Altomonte M, Covre A and Maio M: Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 86:12–19. 2010. View Article : Google Scholar : PubMed/NCBI